Most Popular
1. Dow Max Drawdown Bear Stock Market 2022 - Accumulating Deviations from the Highs - 21st Feb 22
2.Putin Starts WW3 in Ukraine, Will Use Tactical Nuclear Weapons, China Prepares Taiwan Blitzkrieg - 28th Feb 22
3.World War 3 Phase 1 - Putin WINS Ukraine War! - 25th Feb 22
4.INVESTORS SEDUCED by CNBC and the STOCK CHARTS COMPLETELY MISS the BIG PICTURE! - 10th Feb 22
5.Will There Be A 2024 US Presidential Election? - 3rd Mar 22
6.Gold and SIlver, Precious Metals Sector Is at a Terrific Buy Spot - 6th Feb 22
7.Why Putin Wants the WHOLE of Ukraine - World War 3 Untended Consequences - 6th Feb 22
8.Dow Stock Market Expected Max Drawdown 2022 - 19th Feb 22
9.Stock Market Calm In the Eye of the Inflation Storm - 4th Mar 22
10.M = F - Everything is Waving! Stock Market Forward Guidance - 7th Mar 22
Last 7 days
Britain's Hyper Housing Market - 27th May 22
Lower Copper price due to Chinese lockdowns is only Temporary - 27th May 22
How the United States Conquered Inflation Following the Civil War - 27th May 22
Greater Depression Now!? - 27th May 22
Stocks: Is the Really Scary Part Just Ahead? - 27th May 22
The Dark Side of the Internet - Cybersecurity - 27th May 22
Why Ray Dalio is WRONG About China - Principles for Dealing with the Changing World Order - 24th May 22
Globalists Convene to Plan Central Bank Digital Currencies - 24th May 22
After Recent Highs, What’s Next for the Gold Junior Miners? - 24th May 22
Why APPLE Could CRASH the Stock Market! - 21st May 22
Why Is Crude Oil Ignoring US Inventories? - 21st May 22
Here is Why I’m Still Bullish on Gold Mining Stocks - 21st May 22
THE INFLATION MEGA-TREND QE4EVER! - 20th May 22
US Real Estate Investors – Is There An End In Sight? - 20th May 22
How Technology Affected the Gaming Industry - 20th May 22
How To Set And Achieve Reasonable Goals For Your Company - 20th May 22
How Low Could the Amazon (AMZN) Stock Price Fall? - 19th May 22
Bitten by FANG? Clocked by Cryptos? -- 'Air Pockets' Everywhere - 19th May 22
Northern General Hospital Orthopedics Fractures and and Ankle Clinic Consultations Real Patient Experience - 19th May 22
Cathie Wood Goes All in on Teladoc, ARKK INSANE Noob Investing Strategy! - 17th May 22
This is Anything but Positive for US Housing Market - 17th May 22
What Should We Do If There Is No Fed Monetary Policy Pivot? - 17th May 22
All Possible Ways to Earn Free Litecoin - 17th May 22
How low Could the Amazon Stock Price Fall? - 16th May 22
Cathy Wood ARKK INSANITY There is NO Coming Back! - 16th May 22
NASDAQ 100 Stock Market LOWER LOWS & LOWER HIGH - 16th May 22
Sanctions, trade wars worsen US inflation - 16th May 22

Market Oracle FREE Newsletter

How to Protect your Wealth by Investing in AI Tech Stocks

Vaccine Therapies Hold Promise for Investors

Companies / Healthcare Sector Apr 13, 2012 - 06:14 AM GMT

By: The_Energy_Report

Companies

Best Financial Markets Analysis ArticleDeveloping vaccines to treat and/or prevent disease promises life-changing benefits for patients and unique opportunities for investors. In this interview with The Life Sciences Report, LifeTech Capital Senior Managing Director and President Stephen Dunn discusses the roadblocks encountered by some developers of immune therapies and how other companies are working around those obstacles, producing investment opportunities in the process.


The Life Sciences Report: I’d like to talk about preventive and therapeutic immunization. How large is the preventive vaccine market?

Stephen Dunn: According to the World Health Organization, over 12 million (M) people are reported to die from infectious diseases annually, with the unreported figures much higher. In addition, the number of people afflicted with nonfatal infectious diseases is likely near 1 billion (B), which also represents significant global healthcare and economic costs. While difficult to calculate precisely in dollar terms, the global vaccine market is roughly $30B or more, with the U.S. representing $20B or more. We expect this to grow significantly as there are over 300 infectious diseases and only about 15% of them have an effective prophylactic therapy.

TLSR: We know that governments have to be involved in preventive vaccines. Foundations, such as BIO Ventures for Global Health, the Bill and Melinda Gates Foundation, Wellcome Trust, etc., are also involved. Development costs may be subsidized, but margins will be thin for sure. What's the bottom line? How thin will margins be, and can prophylactic vaccines be profitable to companies and their shareholders?

SD: We expect margins on the basic routine immunizations with low incidence to be around 5%, which investors should treat more like an annuity than a growth vehicle. However, vaccines in new indications, especially those in highly contagious or fatal indications, can command significantly higher margins and represent significant investment opportunities. Examples of this are Merck & Co. Inc.'s (MRK:NYSE) Gardasil and GlaxoSmithKline's (NYSE:GSK) Cervarix, prophylactic vaccines for human papillomavirus (HPV), which causes cervical cancer. These have solid profit margins.

TLSR: Shifting to therapeutic immunization, one high-profile major development project that has come to fruition is Dendreon Corp.'s (DNDN:NASDAQ) Provenge. Uptake has been disappointing, and the company has had a very rough year. Does this bode poorly for other therapeutic vaccine developers?

SD: Dendreon's Q411 results were $77M in Provenge sales, with a 26% gross margin. While this looks like a high margin compared to prophylactic vaccines, it is not enough for a therapeutic vaccine. The patient volume is much lower, with only 250,000 (250K) prostate cancer patients who can be treated versus many millions of people receiving prophylactic vaccines. Provenge is patient-specific and must be custom manufactured, so the cost of production, requiring multiple production centers, is significant. The limitations are certainly a concern for patient-specific vaccines, but there are alternative vaccine approaches for investors.

TLSR: Will therapeutic vaccines developed in the future be less expensive than Dendreon's, which costs $93K/year to treat a patient?

SD: I think the entire therapeutic vaccine industry has taken notice of Dendreon's struggle to cover its costs of manufacturing a patient-specific therapeutic vaccine. The pricing issue is driven by the drug's modest effect on prostate cancer survival, and the fact that a number of new, competing therapeutic options are half the cost. Overall, pricing is always a function of benefit versus alternative therapies, the same as for any drug.

For example, Bristol-Myers Squibb Co.'s (BMY:NYSE) Yervoy, for melanoma, is an immunotherapy that inhibits CTLA-4, augmenting T-cell activation and proliferation. Because there are very few options for these melanoma patients, the pricing of Yervoy at $30K per dose, or $120K for four cycles, is not out of line. In addition, this is an "off-the-shelf" therapeutic, meaning it does not require custom manufacturing for each patient, and the gross margins are significantly higher.

TLSR: Is Provenge the classic first-generation prototype, leading the way while those that follow benefit by being able to produce a product that is cheaper and better?

SD: Provenge is a classic first-generation example of a patient-specific vaccine, and illustrates the high manufacturing costs of that approach. One company addressing the manufacturing issue is ImmunoCellular Therapeutics Ltd. (IMUC:OTCBB), which is developing a patient-specific cancer therapeutic vaccine called ICT-107. The difference is that it can manufacture around 20 doses at once for the patient, versus Dendreon, which can only produce a single patient-specific dose at a time. This should result in significantly better economics.

Another vaccine approach is being used by Immunovaccine Inc. (IMV:TSX.V). This company combines seven antigens found in breast, ovarian and prostate cancers in a sustained-release formulation, rather than manufacturing patient-specific vaccines.

Other manufacturing processes, such as those used in DNA vaccines, can design and produce "off-the-shelf" vaccines faster. These represent third-generation technologies. While no therapeutic DNA vaccine has yet been approved, both Vical (VICL:NASDAQ) and Inovio Pharmaceuticals Inc. (INO:NYSE.A) currently have therapeutic DNA vaccines in various cancer clinical trials.

TLSR: How much can an adjuvant be worth to companies engaged in immune system modification—either therapeutic or preventive?

SD: Competing immunotherapies tend to converge on the same antigens in a specific indication, so the differentiator may lie with the adjuvant. Some research has shown that adjuvants may even be more important than the antigen, resulting in them being called "immunology's dirty little secret." In fact, some suggest that Dendreon's Provenge results may not have been a result of the prostate antigen but rather the adjuvant, because it used a placebo control arm. An interesting pure-play in this space is Stellar Biotechnologies Inc. (SBOTF:OTCPK; KLH:TSX.V; RBT:Fkft), which is the world leader in keyhole limpet hemocyanin (KLH) production for use as an adjuvant and protein carrier. KLH is currently being used as either an adjuvant or protein carrier in over 20 active human clinical trials in various indications. One might think of Stellar as an "arms-merchant" to immunotherapy developers.

TLSR: Thanks for your time, Stephen.

SD: My pleasure.

LifeTech Capital Senior Managing Director and President Stephen Dunn was previously the managing director of Life Sciences Research at Jesup & Lamont, as well as director of research for Dawson James Securities and director of Life Sciences at Cabot Adams venture capital group. He has held management positions in business development, finance and operations having worked in over 25 countries in North America, Europe and the Far East with biomedical companies including Beckman Coulter, Coulter, Cordis (Johnson & Johnson), Telectronics (St. Jude Medical) as well as several smaller companies. With over 25 years within the global biomedical industry, Dunn has negotiated numerous intellectual property licenses, product development agreements, venture funding, mergers and aquisitons and joint ventures. Dunn is a five-star biotechnology analyst on StarMine and has appeared in both the financial and scientific media such as The Wall Street Journal, Newsweek, Forbes, Nature Biotechnology, The Scientist, CNN, Nightly Business Report, BioWorld and many other media outlets. He is also a frequent speaker and panel member for many financial, medical and venture capital events.

Want to read more exclusive Life Sciences Report interviews like this? Sign up for our free e-newsletter, and you'll learn when new articles have been published. To see a list of recent interviews with industry analysts and commentators, visit our Exclusive Interviews page.

DISCLOSURE:
1) George Mack conducted this interview. He personally and/or his family own shares of the following companies mentioned in this interview: None.
2) Stephen Dunn: I personally and/or my family own shares of the following companies mentioned in this interview: None. I personally and/or my family am paid by the following companies mentioned in this interview: None. Stellar Biotechnologies is currently an advisory client of LifeTech Capital.
3) The following companies mentioned in the interview are sponsors of The Life Sciences Report: Stellar Biotechnologies Inc.; ImmunoCellular Therapeutics Ltd. Merck & Co. Inc. is not affiliated with Streetwise Reports. Streetwise Reports does not accept stock in exchange for services.

Streetwise – The Life Sciences Report is Copyright © 2012 by Streetwise Reports LLC. All rights are reserved. Streetwise Reports LLC hereby grants an unrestricted license to use or disseminate this copyrighted material (i) only in whole (and always including this disclaimer), but (ii) never in part.

The Life Sciences Report does not render general or specific investment advice and does not endorse or recommend the business, products, services or securities of any industry or company mentioned in this report.

From time to time, Streetwise Reports LLC and its  directors, officers, employees or members of their families, as well as persons interviewed for articles on the site, may have a long or short position in securities mentioned and may make purchases and/or sales of those securities in the open market or otherwise.

Streetwise Reports LLC does not guarantee the accuracy or thoroughness of the information reported.

Streetwise Reports LLC receives a fee from companies that are listed on the home page in the In This Issue section. Their sponsor pages may be considered advertising for the purposes of 18 U.S.C. 1734.

Participating companies provide the logos used in The Life Sciences Report. These logos are trademarks and are the property of the individual companies.

101 Second St., Suite 110
Petaluma, CA 94952

Tel.: (707) 981-8204
Fax: (707) 981-8998

© 2005-2019 http://www.MarketOracle.co.uk - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.


Post Comment

Only logged in users are allowed to post comments. Register/ Log in